Do Prokaryotes Have a Cell Wall? Structure & Function

Most prokaryotes do have a cell wall, but calling it “the prokaryotic cell wall” as though it were one thing glosses over enormous variety. Bacteria typically surround themselves with peptidoglycan, a mesh-like polymer that acts as a pressure-bearing scaffold. Archaea, the other major prokaryotic domain, build their walls from entirely different materials. And a handful of prokaryotes get by with no wall at all. The diversity here is genuinely surprising, and it has real consequences for everything from antibiotic design to how your immune system detects an infection.

The Bacterial Cell Wall and Its Signature Material

Peptidoglycan is the defining component of nearly all bacterial cell walls. It is a large polymer that forms a mesh-like scaffold around the bacterial inner membrane, and it is found in essentially no other domain of life.¹ The building blocks are two alternating sugar molecules linked together into long chains, with short chains of amino acids branching off one of those sugars. Neighboring amino acid branches get stitched together by enzymes, creating a continuous net that wraps the entire cell.² The result is sometimes described as a single enormous bag-shaped molecule, and that description is not far off.

This scaffold has to be strong enough to hold back internal osmotic pressure (turgor) while remaining flexible enough to let the cell grow and divide. Research on E. coli has shown that turgor pressure actually increases with growth rate, and that the pressure itself directly controls how fast new wall material gets added.³ In rod-shaped bacteria, the wall is built with a directional bias so that the cell elongates without ballooning outward, a bit like a woven finger trap that tightens as it stretches.⁴ Without this structural scaffold, most bacteria would simply burst.

How Gram-Positive and Gram-Negative Walls Differ

The classic division in bacteriology is between Gram-positive and Gram-negative organisms, a distinction that traces back to a staining technique but reflects genuinely different wall architectures. Gram-positive bacteria have a thick peptidoglycan layer, many times thicker than what Gram-negatives carry, threaded through with long negatively charged polymers called teichoic acids.⁵ This thick coat sits directly outside the cell membrane and is the outermost structural barrier the cell has.

Gram-negative bacteria take a different approach. Their peptidoglycan layer is thin, but it sits sandwiched between two membranes: the inner (cytoplasmic) membrane and a distinctive outer membrane loaded with a molecule called lipopolysaccharide.⁵ That outer membrane is a formidable barrier in its own right. It blocks many molecules from getting in, which is one reason Gram-negative infections can be harder to treat with antibiotics. To allow nutrients through, the outer membrane is studded with channel-forming proteins called porins that selectively let small molecules pass while keeping larger threats out.

The practical upshot of this architecture goes well beyond staining color. It affects which drugs work, how the immune system recognizes the bacterium, and how the cell responds to environmental stress. An antibiotic that targets peptidoglycan synthesis might kill both types, but getting the drug through the outer membrane of a Gram-negative cell is an additional engineering challenge that drug developers constantly wrestle with.

Archaeal Walls Are a Completely Different Story

Archaea look superficially similar to bacteria under a microscope, but their cell walls are built from fundamentally different materials. No known archaeon uses true peptidoglycan.⁶ Instead, most archaea rely on a surface layer (S-layer) made of protein. These S-layer proteins self-assemble into a flat crystalline sheet that coats the outside of the cell, forming a porous lattice with a repeating geometric pattern.⁷ The proteins interlock in arrangements that can have two-fold, four-fold, or six-fold symmetry, depending on the species.

Some archaea go beyond the S-layer. Certain methane-producing archaea (methanogens) build their walls from pseudomurein, a polymer that superficially resembles peptidoglycan but differs in key chemical details: it uses a different sugar, its sugar linkages have a different geometry, and its amino acid cross-links contain only one mirror-image form of amino acids rather than the mix found in bacterial peptidoglycan.⁸ Other archaea use sugar polymers like methanochondroitin or heteropolysaccharides as their primary wall material, sometimes with an S-layer on top.⁷

This chemical distinctness matters medically. Antibiotics like penicillin and vancomycin work by sabotaging peptidoglycan synthesis, so they are useless against archaea. Lysozyme, an enzyme in your tears and saliva that chews through bacterial peptidoglycan, also has no effect on archaeal walls. Archaea are not known to cause infectious disease in humans, and the absence of a peptidoglycan target is one reason they occupy a very different ecological niche from pathogenic bacteria.

Prokaryotes That Have No Wall at All

Mycoplasmas are the most prominent example of naturally wall-less prokaryotes. These tiny bacteria have permanently lost the genes for making peptidoglycan and rely on a single plasma membrane as their only boundary with the outside world.⁹ To compensate for the missing structural support, mycoplasma membranes incorporate sterols (like cholesterol), which stiffen the membrane enough to prevent the cell from collapsing or rupturing. This sterol requirement is unique among prokaryotes and makes mycoplasmas dependent on their host for a supply of cholesterol.

The absence of a wall has direct clinical consequences. Mycoplasma pneumoniae, which causes a common form of “walking pneumonia,” is inherently resistant to every antibiotic that targets cell wall synthesis. Penicillins, cephalosporins, and vancomycin all miss the mark because there is simply no peptidoglycan to disrupt. Treating mycoplasma infections requires antibiotics that go after other targets, such as protein synthesis or DNA replication.

L-Forms and the Ability to Shed the Wall Temporarily

Beyond permanently wall-less species, many ordinary bacteria can be coaxed into dropping their cell wall under the right conditions. These wall-deficient variants are called L-forms. They arise when a cell wall synthesis inhibitor (like penicillin) is applied in a protective high-salt environment that prevents the cell from bursting.¹⁰ Without their rigid scaffold, L-form cells become blobby and irregularly shaped, dividing through membrane blebbing, budding, and pinching rather than the usual machinery that bacteria use to split in two.¹¹

The remarkable thing is that L-form proliferation works across both Gram-positive and Gram-negative species, suggesting it could be a universal backup mode for bacterial reproduction. Researchers have speculated that this membrane-based division might echo how the earliest cells reproduced before peptidoglycan evolved.¹⁰ When the antibiotic pressure is lifted, L-form cells can revert to their normal walled state, rebuilding the peptidoglycan scaffold and resuming their usual rod or spherical shape.¹²

L-forms are more than a laboratory curiosity. There is growing interest in whether bacteria might hide from antibiotic treatment by switching into the L-form state inside the body, potentially contributing to chronic or relapsing infections. If a bacterium can survive without its wall long enough for antibiotic levels to drop, it could re-emerge in its normal form once conditions improve.

Bacteria That Were Thought to Lack a Wall but Actually Have One

The textbook list of “bacteria without peptidoglycan” has gotten shorter in recent years. For decades, two groups stood out as supposed exceptions: the Chlamydiae and the Planctomycetes. Neither seemed to have detectable peptidoglycan, which was puzzling because both carried genes that should encode the enzymes for making it. Microbiologists called this the “chlamydial anomaly.”

That anomaly was resolved when researchers used advanced imaging and chemical analysis to demonstrate that certain environmental chlamydiae do, in fact, build peptidoglycan cell walls. Treating these chlamydiae with a drug that blocks peptidoglycan synthesis led to lower infection rates and distorted cell shapes, confirming that the wall is functionally important for their life cycle.¹³

The Planctomycetes story ran in parallel. Multiple research groups independently demonstrated that these bacteria, including the ecologically important anammox organisms, possess genuine peptidoglycan sacculi that are susceptible to lysozyme and have the characteristic sugar and amino acid components.¹⁴ Based on the thickness and location of their peptidoglycan, researchers proposed reclassifying Planctomycetes as Gram-negative bacteria, arguing that they are not exceptions to the near-universal presence of peptidoglycan in bacteria at all.¹⁵ These discoveries reinforce just how universal peptidoglycan really is across the bacterial domain. The genuine exceptions are limited to mycoplasmas and a few other highly specialized parasites.

Mycobacteria and Their Waxy Armor

Not all bacterial cell walls fit neatly into the Gram-positive/Gram-negative binary. Mycobacteria, including the species that causes tuberculosis, have peptidoglycan at their core but coat it with an extraordinary layer of mycolic acids, long-chain fatty acids found nowhere else in nature.¹⁶ This waxy outer shell makes the cell extremely hydrophobic and resistant to many chemical assaults, including standard disinfectants and conventional antibiotics. It is also why mycobacteria stain poorly with the Gram technique and require their own staining method entirely.

The mycolic acid layer is both a strength and a vulnerability. It makes tuberculosis infections notoriously difficult to treat, requiring months-long multi-drug regimens. But because the biosynthetic pathway for mycolic acids is unique to mycobacteria, it represents a highly specific drug target. Isoniazid, one of the frontline tuberculosis drugs, works precisely by blocking an enzyme required for mycolic acid production.

How Antibiotics Exploit the Cell Wall

The peptidoglycan wall is the single most important antibiotic target in clinical medicine. Two of the most widely used antibiotic families, beta-lactams (penicillins and cephalosporins) and glycopeptides (like vancomycin), both work by disrupting different steps in the wall’s assembly line. Beta-lactams inhibit the enzymes that cross-link new peptidoglycan strands, while glycopeptides grab onto the precursor building blocks and prevent them from being incorporated at all.¹⁷

The cross-linking enzymes are called penicillin-binding proteins, and they do double duty: they both polymerize new glycan chains and stitch neighboring chains together.¹⁸ When beta-lactam antibiotics occupy these enzymes’ active sites, the cell keeps growing but can no longer maintain structural integrity. Turgor pressure eventually wins, and the cell lyses. This is why beta-lactams are bactericidal, meaning they kill bacteria rather than merely slowing their growth.

The wall assembly pathway has multiple other vulnerable points. Fosfomycin blocks one of the earliest cytoplasmic steps in building the peptidoglycan precursor. Other experimental drugs target the flipping of precursor molecules across the membrane, or the regulatory systems that coordinate wall growth with cell division.¹⁹ Because animal cells have no peptidoglycan at all, these drugs can attack bacterial walls with relatively low toxicity to the patient. That selectivity is the reason cell wall-targeting antibiotics remain the backbone of modern infectious disease treatment.

How Your Immune System Recognizes Peptidoglycan

The immune system does not wait passively for antibiotics. Your body has its own built-in cell wall weapon: lysozyme, an enzyme found in tears, saliva, nasal mucus, and breast milk. Lysozyme cuts the bonds between the sugar units in peptidoglycan, weakening the wall and ultimately killing the bacterium.²⁰ It acts as one of the first lines of defense before the rest of the immune response even gets mobilized.

Beyond direct killing, the fragments of peptidoglycan released by lysozyme serve as alarm signals. When immune cells encounter these fragments, they activate pattern recognition receptors that trigger inflammation and recruit additional immune defenses to the site of infection.²¹ Some bacteria have evolved countermeasures. By chemically modifying their peptidoglycan (for instance, adding acetyl groups to the sugar backbone), certain pathogens make their walls resistant to lysozyme cleavage, effectively hiding from this arm of the immune system.²⁰ This modification is considered a virulence factor, directly contributing to the ability of the bacterium to cause disease.

S-Layers Across Both Domains

S-layers deserve their own mention because they blur the boundary between bacteria and archaea. While S-layers are the primary wall component in most archaea, they also appear in many bacteria, often sitting on top of the peptidoglycan. They are, in fact, among the most commonly observed surface structures across all prokaryotes.²² The proteins that compose S-layers have an intrinsic ability to self-assemble into flat two-dimensional crystals, forming highly porous sheets with unit cells ranging from a few to about 30 nanometers across.

What S-layers actually do varies by species. In some organisms they serve a protective role, acting as a molecular sieve that admits small nutrients while blocking larger threats like enzymes or predatory proteins. In others they help maintain cell shape or regulate the import and export of materials.²³ The self-assembling property of S-layer proteins has also attracted interest from materials scientists, who see them as natural building blocks for constructing nanoscale devices and coatings. Because S-layer proteins spontaneously form ordered lattices under mild conditions, they can serve as templates for patterning other molecules at the nanometer scale.²⁴

What Pseudomurein Tells Us About Evolution

The existence of pseudomurein in methanogens raises an interesting evolutionary puzzle. If bacteria have peptidoglycan and archaea have something chemically similar but clearly different, did their common ancestor have a wall? One line of evidence says yes. Researchers have found that pseudomurein-containing methanogens carry recognizable versions of the same enzyme families that bacteria use to build peptidoglycan, organized in similar gene clusters. Structural analysis of one of these archaeal enzymes confirmed it is clearly related to bacterial cell wall enzymes.²⁵

This suggests that the last common ancestor of bacteria and archaea may have already possessed a cell wall, and that the two lineages diverged from a shared starting point rather than inventing wall-building independently. The chemical differences between murein and pseudomurein would then reflect billions of years of separate evolution within each domain, modifying a shared ancestral blueprint into two distinct polymers. Whether that ancestor’s wall looked more like peptidoglycan, more like pseudomurein, or like something else entirely remains an open question, but the enzymatic kinship between the two pathways is hard to explain any other way.